Another phase II clinical trial of durvalumab in combination with monoclonal antibodies directed against CD20, OX40 and CTLA4 designed to determine the optimal dose of MEDI6469 (anti-OX40) that is safe and tolerable in participants with DLBCL was terminated early at the sponsor's discretion due technical problems (NCT02205333). This evidence concerns the gene CTLA4 and diffuse large B-cell lymphoma.